Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from HFSA Out Now!
2023 | HFSA

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

Industry News In The News

Princeton, NJ – April 26, 2023 — Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of CAMZYOS® (mavacamten) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients. The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP opinion.

“Obstructive hypertrophic cardiomyopathy can be a debilitating and life-changing heart disease, reducing physical functioning and overall well-being, and often runs in families. For patients in the EU, there is yet to be an approved therapy that targets the underlying cause of this disease, despite its global prevalence and debilitating symptoms,” said Roland Chen, M.D., Senior Vice President, Cardiovascular Development at Bristol Myers Squibb. “We are encouraged by the CHMP’s positive recommendation, which puts us one step closer to offering patients in the EU a first-in-class treatment for obstructive HCM, and reinforces our commitment to delivering transformative cardiovascular therapies to patients worldwide.”